levofloxacin and rifapentine

Phase 3Small molecule

MMcGill University Health Centre/Research Institute of the McGill University Health Centre

levofloxacin and rifapentine is one of 46 small molecule programs targeting Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentRecruiting

TreatmentPhase 3

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

levofloxacin and rifapentine

MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 3

1 3

Dexilant

Takeda

Preclinical

2 4

Alfenta

Jazz Pharmaceuticals

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Lotemax

PPharmos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2/3Recruiting

Treatment

NCT06498414

Clinical

Trials by Indication[1]

Treatment1 trial

Shorter and Safer Treatment Regimens for Latent TB

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06498414·1,800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for levofloxacin and rifapentine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — levofloxacin and rifapentine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for levofloxacin and rifapentine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McGill University Health Centre/Research Institute of the McGill University Health Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMcGill University Health Centre/Research Institute of the McGill University Health Centre

levofloxacin and rifapentine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News